Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label primary vaccination study of MenACWY conjugate vaccine versus MenC-CRM197 vaccine in healthy children aged 2 to 10 years
2007-007837-38Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2008
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal conjugate vaccine and Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Immunogenicity one month after vaccination. Started Feb 2008; status: completed.
02
Drugs
meningococcal conjugate vaccineMeningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2007-007837-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007837-38.